Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...

Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially ...

Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...

Roche has dived into the data behind its filing for FDA approval of fenebrutinib in multiple sclerosis (MS), unpacking the ...

| GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, ...

Medtech M&A reached its highest level in more than a decade, EY found, with a total disclosed deal value of roughly $130 ...

Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...

Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...